+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva, Tissue, Urine) by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End-use, by Region, and Segment Forecasts, 2025-2033- Product Image
Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva, Tissue, Urine) by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End-use, by Region, and Segment Forecasts, 2025-2033- Product Image
New

Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva, Tissue, Urine) by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End-use, by Region, and Segment Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • August 2025
  • Region: Global
  • Grand View Research
  • ID: 6168187
Description Jump to:
The global biomarker-based immunoassays market size was valued at USD 5.15 billion in 2024 and is expected to reach USD 8.33 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. The market growth is fueled by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools.

Increasing demand for personalized medicine has driven clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring. The increasing reliance on companion diagnostics, along with regulatory support for biomarker-driven disease development, has solidified immunoassays as an essential technology in modern healthcare. Additionally, public and private investments in translational research and clinical diagnostics have sped up adoption across hospitals, laboratories, and academic institutions.

Technological advancements are also reshaping the scope of the market, with multiplexing platforms, high-throughput analyzers, and next-generation immunoassay systems enabling the simultaneous detection of multiple biomarkers with enhanced sensitivity and specificity. The integration of artificial intelligence (AI) and machine learning (ML) into biomarker-based testing improves data interpretation, while liquid biopsy-based immunoassays offer less invasive options for oncology and neurology diagnostics. Companies are also developing reagents and kits tailored for predictive and prognostic biomarkers, which are increasingly valuable in precision medicine. These innovations not only enhance diagnostic accuracy but also reduce turnaround times, making biomarker immunoassays more accessible and clinically relevant.

Global Biomarker-based Immunoassays Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the biomarker-based immunoassays market on the basis sample, product, biomarkers, diseases, end-use, and region:

Sample Outlook (Revenue, USD Million, 2021-2033)

  • Blood
  • Tissue
  • Urine
  • Saliva

Product Outlook (Revenue, USD Million, 2021-2033)

  • Consumables
  • Instruments/ Analyzers
  • Reagent & Kits
  • Services

Biomarker Outlook (Revenue, USD Million, 2021-2033)

  • Safety & toxicity biomarkers
  • Efficacy & Pharmacodynamic Biomarkers
  • Predictive & Prognostic Biomarkers
  • Surrogate/Exploratory Biomarkers

Diseases Outlook (Revenue, USD Million, 2021-2033)

  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others

End-use Outlook (Revenue, USD Million, 2021-2033)

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Sample Segment
1.2.2. Product Segment
1.2.3. Biomarker Segment
1.2.4. Diseases Segment
1.2.5. End Use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Biomarkerl
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Global Biomarker-Based Immunoassays Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising demand for precision medicine and personalized therapies
3.2.1.2. Increasing prevalence of chronic and infectious diseases
3.2.1.3. Technological advancements in immunoassay platforms
3.2.2. Market restraint analysis
3.2.2.1. High cost of advanced biomarker assays and platforms
3.3. Global Biomarker-Based Immunoassays Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Global Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Biomarker-Based Immunoassays Market Sample Movement Analysis
4.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2030 (USD Million)
4.4. Blood
4.4.1. Blood market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Tissue
4.5.1. Tissue market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Saliva
4.6.1. Saliva market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Urine
4.7.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Global Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Biomarker-Based Immunoassays Market Product Movement Analysis
5.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
5.4. Consumables
5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Instruments/Analyzers
5.5.1. Instruments/Analyzers market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Reagent & Kits
5.6.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Services
5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Global Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Biomarker-Based Immunoassays Market Biomarker Movement Analysis
6.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
6.4. Safety & toxicity biomarkers
6.4.1. Safety & toxicity biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Efficacy & Pharmacodynamic Biomarkers
6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Predictive & Prognostic Biomarkers
6.6.1. Predictive & prognostic biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Surrogate/Exploratory Biomarkers
6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Global Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Biomarker-Based Immunoassays Market Diseases Movement Analysis
7.2.1. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
7.3. Cancer
7.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
7.4. Cardiovascular Diseases
7.4.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Neurological Diseases
7.5.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Immunological Diseases
7.6.1. Immunological diseases testing market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Others
7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Global Biomarker-Based Immunoassays Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Global Biomarker-Based Immunoassays Market End Use Movement Analysis
8.2.1. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.3. Hospitals & Clinics
8.3.1. Hospitals and clinics market estimates and forecasts 2021 to 2033 (USD Million)
8.4. Diagnostic Laboratories
8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Research & Academic Institutes
8.5.1. Research & Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Others
8.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis
9.1. Regional Dashboard
9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
9.3. North America
9.3.1. U.S.
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework/ reimbursement structure
9.3.1.3. Competitive scenario
9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
9.3.2. Canada
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework/ reimbursement structure
9.3.2.3. Competitive scenario
9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
9.3.3. Mexico
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework/ reimbursement structure
9.3.3.3. Competitive scenario
9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Regulatory framework/ reimbursement structure
9.4.1.3. Competitive scenario
9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework/ reimbursement structure
9.4.2.3. Competitive scenario
9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework/ reimbursement structure
9.4.3.3. Competitive scenario
9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework/ reimbursement structure
9.4.4.3. Competitive scenario
9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework/ reimbursement structure
9.4.5.3. Competitive scenario
9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
9.4.6. Norway
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework/ reimbursement structure
9.4.6.3. Competitive scenario
9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework/ reimbursement structure
9.4.7.3. Competitive scenario
9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
9.4.8. Denmark
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework/ reimbursement structure
9.4.8.3. Competitive scenario
9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
9.5. Asia-Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/ reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/ reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework/ reimbursement structure
9.5.3.3. Competitive scenario
9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework/ reimbursement structure
9.5.4.3. Competitive scenario
9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
9.5.5. South Korea
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework/ reimbursement structure
9.5.5.3. Competitive scenario
9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework/ reimbursement structure
9.5.6.3. Competitive scenario
9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/ reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/ reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
9.7. MEA
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/ reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/ reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/ reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/ reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company/Competition Categorization
10.2. Strategy Mapping
10.3. Company Market Share Analysis, 2024
10.4. List of Key Certification Providers/Scheme Owners
10.5. Company Profiles/Listing
10.5.1. F. Hoffmann-La Roche AG
10.5.1.1. Company overview
10.5.1.2. Financial performance
10.5.1.3. Product benchmarking
10.5.1.4. Strategic initiatives
10.5.2. Abbott
10.5.2.1. Company overview
10.5.2.2. Financial performance
10.5.2.3. Product benchmarking
10.5.2.4. Strategic initiatives
10.5.3. Thermo Fisher Scientific Inc
10.5.3.1. Company overview
10.5.3.2. Financial performance
10.5.3.3. Product benchmarking
10.5.3.4. Strategic initiatives
10.5.4. Eurofins Scientific
10.5.4.1. Company overview
10.5.4.2. Financial performance
10.5.4.3. Product benchmarking
10.5.4.4. Strategic initiatives
10.5.5. QIAGEN
10.5.5.1. Company overview
10.5.5.2. Financial performance
10.5.5.3. Product benchmarking
10.5.5.4. Strategic initiatives
10.5.6. Bio-Rad Laboratories, Inc.
10.5.6.1. Company overview
10.5.6.2. Financial performance
10.5.6.3. Product benchmarking
10.5.6.4. Strategic initiatives
10.5.7. Siemens Healthineers AG
10.5.7.1. Company overview
10.5.7.2. Financial performance
10.5.7.3. Product benchmarking
10.5.7.4. Strategic initiatives
10.5.8. Merck KGaA
10.5.8.1. Company overview
10.5.8.2. Financial performance
10.5.8.3. Product benchmarking
10.5.8.4. Strategic initiatives
10.5.9. PerkinElmer Inc.
10.5.9.1. Company overview
10.5.9.2. Financial performance
10.5.9.3. Product benchmarking
10.5.9.4. Strategic initiatives
10.5.10. Agilent Technologies, Inc.
10.5.10.1. Company overview
10.5.10.2. Financial performance
10.5.10.3. Product benchmarking
10.5.10.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 U.S. biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 4 U.S. biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 5 U.S. biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 6 U.S. biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 7 U.S. biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 8 North America biomarker-based immunoassays market, by region, 2021-2033 (USD Million)
Table 9 North America biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 10 North America biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 11 North America biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 12 North America biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 13 North America biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 14 Canada biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 15 Canada biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 16 Canada biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 17 Canada biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 18 Canada biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 19 Mexico biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 20 Mexico biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 21 Mexico biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 22 Mexico biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 23 Mexico biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 24 Europe biomarker-based immunoassays market, by region, 2021-2033 (USD Million)
Table 25 Europe biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 26 Europe biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 27 Europe biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 28 Europe biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 29 Europe biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 30 UK biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 31 UK biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 32 UK biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 33 UK biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 34 UK biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 35 Germany biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 36 Germany biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 37 Germany biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 38 Germany biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 39 Germany biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 40 France biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 41 France biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 42 France biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 43 France biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 44 France biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 45 Italy biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 46 Italy biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 47 Italy biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 48 Italy biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 49 Italy biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 50 Spain biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 51 Spain biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 52 Spain biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 53 Spain biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 54 Spain biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 55 Denmark biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 56 Denmark biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 57 Denmark biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 58 Denmark biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 59 Denmark biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 60 Sweden biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 61 Sweden biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 62 Sweden biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 63 Sweden biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 64 Sweden biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 65 Norway biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 66 Norway biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 67 Norway biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 68 Norway biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 69 Norway biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 70 Asia-Pacific biomarker-based immunoassays market, by region, 2021-2033 (USD Million)
Table 71 Asia-Pacific biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 72 Asia-Pacific biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 73 Asia-Pacific biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 74 Asia-Pacific biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 75 Asia-Pacific biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 76 Japan biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 77 Japan biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 78 Japan biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 79 Japan biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 80 Japan biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 81 China biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 82 China biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 83 China biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 84 China biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 85 China biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 86 India biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 87 India biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 88 India biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 89 India biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 90 India biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 91 Australia biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 92 Australia biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 93 Australia biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 94 Australia biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 95 Australia biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 96 South Korea biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 97 South Korea biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 98 South Korea biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 99 South Korea biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 100 South Korea biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 101 Thailand biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 102 Thailand biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 103 Thailand biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 104 Thailand biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 105 Thailand biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 106 Latin America biomarker-based immunoassays market, by region, 2021-2033 (USD Million)
Table 107 Latin America biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 108 Latin America biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 109 Latin America biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 110 Latin America biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 111 Latin America biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 112 Brazil biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 113 Brazil biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 114 Brazil biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 115 Brazil biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 116 Brazil biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 117 Argentina biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 118 Argentina biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 119 Argentina biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 120 Argentina biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 121 Argentina biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 122 MEA biomarker-based immunoassays market, by region, 2021-2033 (USD Million)
Table 123 MEA biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 124 MEA biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 125 MEA biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 126 MEA biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 127 MEA biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 128 South Africa biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 129 South Africa biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 130 South Africa biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 131 South Africa biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 132 South Africa biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 133 Saudi Arabia biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 134 Saudi Arabia biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 135 Saudi Arabia biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 136 Saudi Arabia biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 137 Saudi Arabia biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 138 UAE biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 139 UAE biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 140 UAE biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 141 UAE biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 142 global biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
Table 143 Kuwait biomarker-based immunoassays market, by sample, 2021-2033 (USD Million)
Table 144 Kuwait biomarker-based immunoassays market, by product, 2021-2033 (USD Million)
Table 145 Kuwait biomarker-based immunoassays market, by biomarkers, 2021-2033 (USD Million)
Table 146 Kuwait biomarker-based immunoassays market, by diseases, 2021-2033 (USD Million)
Table 147 Kuwait biomarker-based immunoassays market, by end use, 2021-2033 (USD Million)
List of Figures
Figure 1 Global biomarker-based immunoassays market segmentation
Figure 2 Data analysis biomarkers
Figure 3 Market formulation and validation
Figure 4 Data validating & publishing
Figure 5 Market research process
Figure 6 Information procurement
Figure 7 Primary research
Figure 8 Value-chain-based sizing & forecasting
Figure 9 QFD biomarker modelling for market share assessment
Figure 10 Market formulation & validation
Figure 11 Commodity flow analysis
Figure 12 Market outlook
Figure 13 Segment snapshot-1
Figure 14 Segment snapshot-2
Figure 15 Competitive landscape snapshot
Figure 16 Market trends & outlook
Figure 17 Porter’s five force analysis
Figure 18 PESTEL analysis
Figure 19 Global biomarker-based immunoassays market: Sample outlook key takeaways
Figure 20 Global biomarker-based immunoassays market: Sample movement analysis
Figure 21 Blood market estimates and forecasts, 2021-2033 (USD Million)
Figure 22 Tissue market estimates and forecasts, 2021-2033 (USD Million)
Figure 23 Saliva market estimates and forecasts, 2021-2033 (USD Million)
Figure 24 Urine market estimates and forecasts, 2021-2033 (USD Million)
Figure 25 Global biomarker-based immunoassays market: Product outlook key takeaways
Figure 26 Global biomarker-based immunoassays market: Product movement analysis
Figure 27 Consumables market estimates and forecasts, 2021-2033 (USD Million)
Figure 28 Instruments/Analyzers market estimates and forecasts, 2021-2033 (USD Million)
Figure 29 Reagent & kits market estimates and forecasts, 2021-2033 (USD Million)
Figure 30 Services market estimates and forecasts, 2021-2033 (USD Million)
Figure 31 Global biomarker-based immunoassays market: Biomarker outlook key takeaways
Figure 32 Global biomarker-based immunoassays market: Biomarker movement analysis
Figure 33 Safety & toxicity biomarkers market estimates and forecasts, 2021-2033 (USD Million)
Figure 34 Efficacy & pharmacodynamic biomarkers market estimates and forecasts, 2021-2033 (USD Million)
Figure 35 Predictive & prognostic biomarkers market estimates and forecasts, 2021-2033 (USD Million)
Figure 36 Surrogate/Exploratory biomarkers estimates and forecasts, 2021-2033 (USD Million)
Figure 37 Global biomarker-based immunoassays market: Biomarker outlook key takeaways
Figure 38 Global biomarker-based immunoassays market: Biomarker movement analysis
Figure 39 Cancer market estimates and forecasts, 2021-2033 (USD Million)
Figure 40 Cardiovascular diseases market estimates and forecasts, 2021-2033 (USD Million)
Figure 41 Neurological diseases market estimates and forecasts, 2021-2033 (USD Million)
Figure 42 Immunological diseases market estimates and forecasts, 2021-2033 (USD Million)
Figure 43 OtherOthers market estimates and forecasts, 2021-2033 (USD Million)
Figure 44 Global biomarker-based immunoassays market: End Use outlook key takeaways
Figure 45 Global biomarker-based immunoassays market: End Use movement analysis
Figure 46 Hospitals and clinics market estimates and forecasts, 2021-2033 (USD Million)
Figure 47 Diagnostic laboratories market estimates and forecasts, 2021-2033 (USD Million)
Figure 48 Research & academic institutes market estimates and forecasts, 2021-2033 (USD Million)
Figure 49 Others estimates and forecasts, 2021-2033 (USD Million)
Figure 50 Biomarker-based immunoassays market: Regional outlook and key takeaways
Figure 51 Regional outlook, 2024 & 2030
Figure 52 North America
Figure 53 North America market estimates and forecast, 2021-2033 (USD Million)
Figure 54 U.S. key country dynamics
Figure 55 U.S. market estimates and forecast, 2021-2033 (USD Million)
Figure 56 Canada key country dynamics
Figure 57 Canada market estimates and forecast, 2021-2033 (USD Million)
Figure 58 Europe
Figure 59 Europe market estimates and forecast, 2021-2033 (USD Million)
Figure 60 UK key country dynamics
Figure 61 UK market estimates and forecast, 2021-2033 (USD Million)
Figure 62 Germany
Figure 63 Germany market estimates and forecast, 2021-2033 (USD Million)
Figure 64 France key country dynamics
Figure 65 France market estimates and forecast, 2021-2033 (USD Million)
Figure 66 Italy key country dynamics
Figure 67 Italy market estimates and forecast, 2021-2033 (USD Million)
Figure 68 Spain key country dynamics
Figure 69 Spain market estimates and forecast, 2021-2033 (USD Million)
Figure 70 Denmark key country dynamics
Figure 71 Denmark market estimates and forecast, 2021-2033 (USD Million)
Figure 72 Sweden key country dynamics
Figure 73 Sweden market estimates and forecast, 2021-2033 (USD Million)
Figure 74 Norway key country dynamics
Figure 75 Norway market estimates and forecast, 2021-2033 (USD Million)
Figure 76 Asia-Pacific
Figure 77 Asia-Pacific market estimates and forecast, 2021-2033 (USD Million)
Figure 78 Japan key country dynamics
Figure 79 Japan market estimates and forecast, 2021-2033 (USD Million)
Figure 80 China key country dynamics
Figure 81 China market estimates and forecast, 2021-2033 (USD Million)
Figure 82 India key country dynamics
Figure 83 India market estimates and forecast, 2021-2033 (USD Million)
Figure 84 South Korea key country dynamics
Figure 85 South Korea market estimates and forecast, 2021-2033 (USD Million)
Figure 86 Australia key country dynamics
Figure 87 Australia market estimates and forecast, 2021-2033 (USD Million)
Figure 88 Thailand key country dynamics
Figure 89 Thailand market estimates and forecast, 2021-2033 (USD Million)
Figure 90 Latin America
Figure 91 Latin America market estimates and forecast, 2021-2033 (USD Million)
Figure 92 Brazil key country dynamics
Figure 93 Brazil market estimates and forecast, 2021-2033 (USD Million)
Figure 94 Mexico key country dynamics
Figure 95 Mexico market estimates and forecast, 2021-2033 (USD Million)
Figure 96 Argentina key country dynamics
Figure 97 Argentina market estimates and forecast, 2021-2033 (USD Million)
Figure 98 Middle East & Africa
Figure 99 MEA market estimates and forecast, 2021-2033 (USD Million)
Figure 100 South Africa key country dynamics
Figure 101 South Africa market estimates and forecast, 2021-2033 (USD Million)
Figure 102 Saudi Arabia key country dynamics
Figure 103 Saudi Arabia market estimates and forecast, 2021-2033 (USD Million)
Figure 104 UAE key country dynamics
Figure 105 UAE market estimates and forecast, 2021-2033 (USD Million)
Figure 106 Kuwait key country dynamics
Figure 107 Kuwait market estimates and forecast, 2021-2033 (USD Million)
Figure 108 Market differentiators
Figure 109 Key company market share analysis, 2024

Companies Mentioned

The major companies profiled in this Biomarker-based Immunoassays market report include:
  • F. Hoffmann-La Roche AG
  • Abbott
  • Thermo Fisher Scientific Inc
  • Eurofins Scientific
  • QIAGEN
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Merck KGaA
  • PerkinElmer Inc.
  • Agilent Technologies, Inc.

Table Information

Report AttributeDetails
No. of Pages150
PublishedAugust 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 5.15 Billion
Forecasted Market Value ( USD ) by 2033 $ 8.33 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Middle East & Africa Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva) by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End-use, by Country, and Segment Forecasts, 2025-2033 - Product Image

Middle East & Africa Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva) by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End-use, by Country, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Africa, Middle East
From
U.S. Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva), by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End Use, and Segment Forecasts, 2025-2033 - Product Image

U.S. Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report by Sample (Blood, Saliva), by Product (Reagents & Kits, Consumables), by Biomarker, by Diseases, by End Use, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis by Type (Amyloid-related Markers, Tau-related markers, Neurodegeneration), by Technology, by End Use, and Segment Forecasts, 2025-2033 - Product Image

U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis by Type (Amyloid-related Markers, Tau-related markers, Neurodegeneration), by Technology, by End Use, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
U.S. Blood-based Biomarker For Parkinson's Disease Market Size, Share & Trends Analysis Report By Biomarker Type (Protein Biomarkers, Inflammatory Markers), By Technology (ELISA/Immunoassay, Multiplex Platforms), By End Use, And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Blood-based Biomarker For Parkinson's Disease Market Size, Share & Trends Analysis Report By Biomarker Type (Protein Biomarkers, Inflammatory Markers), By Technology (ELISA/Immunoassay, Multiplex Platforms), By End Use, And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • United States
From
Middle East & Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Type (Amyloid-related Markers, Tau-related Markers), by Technology, by End-use, by Country, and Segment Forecasts, 2025-2033 - Product Image

Middle East & Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report by Type (Amyloid-related Markers, Tau-related Markers), by Technology, by End-use, by Country, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Africa, Middle East
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.